101 related articles for article (PubMed ID: 2404579)
1. Radiolabeled antibodies: results and potential in cancer therapy.
Order SE; Sleeper AM; Stillwagon GB; Klein JL; Leichner PK
Cancer Res; 1990 Feb; 50(3 Suppl):1011s-1013s. PubMed ID: 2404579
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric aspects of radiolabeled antibodies for tumor therapy.
Humm JL
J Nucl Med; 1986 Sep; 27(9):1490-7. PubMed ID: 3528417
[TBL] [Abstract][Full Text] [Related]
4. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
5. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
6. Systemic targeted radionuclide therapy: potential new areas.
Wong JY
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
[TBL] [Abstract][Full Text] [Related]
7. [Intra-arterial regional administration of radioactive preparations in treating malignant tumors].
Bardychev MS; Androsov NS; Nikitina RG
Vopr Onkol; 1978; 24(1):99-109. PubMed ID: 345623
[No Abstract] [Full Text] [Related]
8. Outpatient administration of radiolabeled monoclonal antibodies.
Tuinstra N
Clin J Oncol Nurs; 2003; 7(1):106-8. PubMed ID: 12629945
[No Abstract] [Full Text] [Related]
9. International Clinical Trials in Radiation Oncology. Isotopic immunotherapy: radiolabelled antibody.
Order SE
Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S77-81. PubMed ID: 3292485
[TBL] [Abstract][Full Text] [Related]
10. Current status of radioimmunoglobulins in the treatment of human malignancy.
Order SE; Sleeper AM; Stillwagon GB; Klein TL; Leichner PK
Oncology (Williston Park); 1989 May; 3(5):115-20; discussion 122, 129-30. PubMed ID: 2491440
[TBL] [Abstract][Full Text] [Related]
11. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
12. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
Barendswaard EC; O'Donoghue JA; Larson SM; Tschmelitsch J; Welt S; Finn RD; Humm JL
J Nucl Med; 1999 Oct; 40(10):1764-8. PubMed ID: 10520720
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
14. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.
Ruan S; O'Donoghue JA; Larson SM; Finn RD; Jungbluth A; Welt S; Humm JL
J Nucl Med; 2000 Nov; 41(11):1905-12. PubMed ID: 11079503
[TBL] [Abstract][Full Text] [Related]
16. Tumor control probability for tumor therapy with beta radionuclide interstitial injection.
Chen Y; Geng J; Tian J; He Y; Chen S
Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245
[No Abstract] [Full Text] [Related]
17. Radioimmunoglobulin therapy of cancer.
Order SE
Compr Ther; 1984 Jan; 10(1):9-18. PubMed ID: 6692670
[No Abstract] [Full Text] [Related]
18. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
19. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
20. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
Palm A; Johansson KA
Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
